PD GSK3 Inhibitor Companies

PD GSK3 Inhibitor Companies

Overview

Glycogen synthase kinase 3 beta (GSK-3beta) is a serine/threonine kinase that plays a central role in Parkinson's disease pathogenesis through its effects on tau hyperphosphorylation, alpha-synuclein (alpha-syn) phosphorylation and aggregation, mitochondrial dysfunction, and neuroinflammation. GSK-3beta represents one of the most compelling therapeutic targets for disease modification in PD["@gsk3_parkinsons_review"].

GSK3β in Parkinson's Disease Pathogenesis

PD GSK3 Inhibitor Companies

Overview

Glycogen synthase kinase 3 beta (GSK-3beta) is a serine/threonine kinase that plays a central role in Parkinson's disease pathogenesis through its effects on tau hyperphosphorylation, alpha-synuclein (alpha-syn) phosphorylation and aggregation, mitochondrial dysfunction, and neuroinflammation. GSK-3beta represents one of the most compelling therapeutic targets for disease modification in PD["@gsk3_parkinsons_review"].

GSK3β in Parkinson's Disease Pathogenesis

GSK-3β is constitutively active in neurons and its activity is regulated by inhibitory phosphorylation at Ser9. In PD, this inhibitory mechanism is impaired, leading to increased kinase activity that promotes pathological protein aggregation and neuronal death. The kinase also phosphorylates α-syn at Ser129, a modification abundant in Lewy bodies[@gsk3_alpha_syn].

Tau Hyperphosphorylation

GSK-3β is one of the principal kinases responsible for tau hyperphosphorylation in PD, phosphorylating tau at multiple sites including Thr181, Ser202, Thr205, Ser396, and Ser404, promoting microtubule disassembly and neurofibrillary tangle formation.

Alpha-Synuclein Phosphorylation

GSK-3β phosphorylates α-syn at multiple sites, with Ser129 being the most studied. The relationship between GSK-3β activity and α-syn pathology is context-dependent.

Mitochondrial Dysfunction

GSK-3β contributes to mitochondrial dysfunction in PD through inhibition of mitochondrial biogenesis via PGC-1α, promotion of mitochondrial permeability transition, regulation of mitophagy through Parkin and PINK1, and enhancement of mitochondrial oxidative stress.

Companies Developing GSK3 Inhibitors for PD

Lithium-Based Approaches

Lithium is a first-generation GSK3 inhibitor used clinically for bipolar disorder. It inhibits GSK-3β both directly and indirectly through Akt-mediated Ser9 phosphorylation[@lithium_parkinsons]:

• Lithium carbonate formulations: Generic, widely available, brain-penetrant
• Lithium orotate: Alternative formulation with different pharmacokinetics

Selective GSK3 Inhibitors

Tideglusib (Neuroab)

Tideglusib is a selective, irreversible GSK3 inhibitor developed by Nostrum. It has been evaluated in clinical trials for Alzheimer's disease with a favorable safety profile[@tideglusib_trials]:

• Target: GSK-3α and GSK-3β
• Status: Completed Phase II for AD
• PD potential: Targets tau and α-syn phosphorylation

AR-A014418

AR-A014418 is a selective ATP-competitive GSK3 inhibitor developed by AstraZeneca:

• Target: GSK-3β (selective)
• Evidence: Neuroprotective in MPTP models

CHIR99021

CHIR99021 is a selective GSK3 inhibitor used in research to enhance Wnt signaling:

• Target: GSK-3β (selective)
• Evidence: Promotes dopaminergic neuron survival

Clinical Trial Landscape

Completed Trials

| Compound | Indication | Phase | Status |
|----------|------------|-------|--------|
| Tideglusib | Alzheimer's | Phase II | Completed |
| Lithium | PD | Various | Completed |

Therapeutic Development Challenges

• Selectivity: Difficulty achieving isoform selectivity between GSK-3α and GSK-3β
• Brain Penetration: Many early inhibitors failed to achieve adequate brain penetration
• Therapeutic Window: Narrow window between neuroprotective and toxic doses
• Mechanism Complexity: Dual role of GSK-3β in both promoting and potentially preventing α-syn aggregation

Conclusion

GSK3β represents a compelling therapeutic target in Parkinson's disease. While no selective GSK3 inhibitors have reached late-stage clinical development specifically for PD, lithium remains the most clinically tested GSK3 inhibitor for neurological applications.

See also [GSK3 in Parkinson's Disease](/mechanisms/gsk3-parkinsons), [GSK3 in Parkinson's Disease - Disease Focus](/mechanisms/gsk3-parkinsons-disease), and [PD Kinase Inhibitor Companies](/companies/pd-lrrk2-kinase-inhibitor-companies).

References

Pathway Diagram

The following diagram shows the key molecular relationships involving PD GSK3 Inhibitor Companies discovered through SciDEX knowledge graph analysis: